

Department of Health Research Ministry of Health and Family Welfare, Government of India



 $\bigcirc \bigcirc$






STANDARD TREATMENT WORKFLOWS STANDARD of India

PARTNERS







STANDARD TREATMENT WORKFLOWS of India





Department of Health Research Ministry of Health and Family Welfare, Government of India

> These STWs have been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit our web portal (**stw.icmr.org.in**) for more information.

> © Indian Council of Medical Research and Department of Health Research, Ministry of Health & Family Welfare, Government of India.

Suggested Citation: Standard Treatment Workflows of India, 2022, Edition, Vol. 3, New Delhi, Indian Council of Medical Research, Department of Health Research, Ministry of Health and Family Welfare, Government of India.

© DHR and ICMR

All rights reserved. No part of these workflows may be transmitted or reproduced in any form or by any means without prior permission from the organization.

Printed in India

CONTENTS

- INTRODUCTION
- SPECIALITIES COVERED IN THIS EDITION

- Endocrinology

Diabetes Type I Diabetes Type II Diabetic Ketoacidosis Fragility Fractures Hyponatremia Hypothyroidism



INTRODUCTION

GOAL


To empower the primary, secondary and tertiary health care physicians/surgeons towards achieving the overall goal of Universal Health Coverage with disease management protocols and pre-defined referral mechanisms by decoding complex guidelines.

OBJECTIVES


To formulate treatment algorithms for common and serious medical & surgical conditions for both outdoor & indoor patient management at primary, secondary and tertiary levels of India's healthcare system that are scientific, robust and locally contextual.

METHODOLOGY

• HBP of AB-PMJAY








ENDOCRINOLOGY





Standard Treatment Workflow (STW) APPROACH TO HYPONATREMIA ICD-10-E87.1



This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (**stw.icmr.org.in**) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.





Standard Treatment Workflow (STW) DIABETES MELLITUS TYPE 1 ICD-10-E10

	Polydipsia		DIAGNOSIS				
FET	Poly	uria / Nocturia	 Diagnosis of diabetes: Fasting plasma glucose ≥ 126 mg%; post-glucose ≥ 200 mg%; HbA1c ≥ 6.5% (all to 				
	Polyphagia			be re-confirmed); random glucose ≥ 200 mg% with symptoms • Characteristic of T1 diabetes; urine/blood ketones:			
	Weight loss			 moderate-large (in > 50%) Continuous requirement of insulin since diagnosis 			
	Short duration of complaints		INVESTIGATIONS				
Diabetic ketoacidosis as first presentation			HbAlc, creatinine, hemoglobin, TSH, tTG (tissue transglutaminase) antibody, lipid profile				
AMBULATORY MANAGEMENT							
 NUTRITION Calories should be appropriate to the expected body weight, pubertal status, activity Balanced diet including all food groups Simple sugars and excessive fats to be avoided 		 Beneficial and should be encouraged 	 Should be checked more frequently in case A1c is not controlled, frequent hypoglycemia Glucose at midnight (12.00-2.00 am) occasionally to rule out nocturnal hypoglycemia Ketones should be checked if blood glucose is > 250 mg/dl 				
		INSULIN TREAT					
Insulin administration (0.25 to 1.0U/kg depending on age and pubertal status) Basal: glargine or detemir or NPH 4 requirement •Bolus: regular or rapid acting 50% of requirement/3 injections before				9% of daily ly	Insulin doses can be adjusted depending upon 1. Pre-meal and post-meal glucose level 2.Carbohydrates in the meal 3.Excercise pattern		
REASONS FOR REFERRAL TO HIGHER CENTRES							

Uncontrolled

For education of patient & family For insulin injection techniques/

Recurrent

Severe diabetic ketoacidosis (altered sensorium, rapid Chronic diabetes specific

hyperglycemia	For insulin injection techn SBGM/ identifying hypoglyc	bypodlycomia		(2	breathing)	specific complications		
	MONITORING							
AT EVERY VISIT • Growth & pubertal development (for children and adolescents)EVERY THREE • Glycated h (HbAlc)		ced her c) t: <7% (s	hemoglobin '% (should be		 COMPLICATIONS & COMORBIDITIES (5 YEARS AFTER DIAGNOSIS, THEN ANNUALLY) Fundus examination (Retinopathy) Foot examination (Neuropathy) Urine albumin/creatinine ratio Other investigations (S-creatinine, TSH), lipid profile 			
SIC	SICK DAY RULES/DKA HYPOGLYCAEMIA							
 IN CASE OF SICKNESS / INFECTION Measure glucose frequently, check for urine ketones if glucose >250 mg% 				 Symptoms and signs: Sweating, hunger, tremors, irritability, weakness, drowsiness / seizures / unconsciousness (late stage) Diagnosis: Mild / moderate: glucose <70 mg% with 				
	of fluids, monitor urine out	put		or without symptoms				
 •Eat small light meals 4-5 times/day •In addition to usual insulin doses, take extra regular insulin s.c. every 6 hourly (10-15% of total 				 Severe hypoglycemia: coma / seizures / inability to treat oneself 				
daily insulin o	dose)			• Treatment: If glucose <70 mg% take 3 tsf glucose				
 If glucose not falling, excess vomiting, low urine output, high or rising ketone, admit the patient DKA MANAGEMENT 			powder or sugar; if severe: caregiver should give inj. glucagon 1 mg s.c./ i.m. OTHERWISE IMMEDIATELY take to hospital for intravenous glucose injection (1-2 ml/kg of 25% dextrose)					
DKA MANAGEMENT • As per STW on Diabetic Ketoacidosis (DKA)				• Prevention: Identify mismatch of food, exercise, insulin				

ABBREVIATIONS

BP: Blood pressure **DKA:** Diabetic ketoacidosis

SBMG: Self-monitoring of blood glucose **TSH:** Thyroid-stimulating hormone **tTG:** Tissue transglutaminase

REFERENCES

1. American Diabetes Association; Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers. Clin Diabetes 1 January 2022; 40 (1): 10–38. https://doi.org/10.2337/cd22-as01

T KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (**stw.icmr.org.in**) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.







Standard Treatment Workflow (STW) DIABETES MELLITUS TYPE 2

ICD-10-E11

	May be asymptomatic		DIAGNOSIS							
	Osmotio sympton ie., polyur	ns 'ia,	Recurrent infections	FPG ≥12 mg/dl		2-h pla glucose	e ≥200	HbA	JC ≥	Diabetes symptoms + random
SYMPTOMS () polydips polypl			Blurring of vision	(after 8h fasting)	Ir 🛛	during	/01	6.5	0%	plasma glucose ≥ 200 mg/dl
	Weight loss			PREDIABETES: Impaired fasting glucose: FPG 100-125 mg/dL; Impaired					Impaired	
	Non heali wounds	Develoption			•••	ce: 140-199 mg/dL; HbA1c 5.7-6.4%				
			AS	SESS						
	rtension Didaemia CAI	D CKD	EXAMINATION: V	3MI vaist E nference	3P P	Periphera pulses	Pin-pri sensatio monofilar test ,vibra DTR	on, ment ition,	Skin, oral cavity, foot	Fundus (dilated) examination
 INVESTIGATION HbAlc Creatinine K⁺ Fasting lipid profile Urine routine exam and spot albumin: or ratio# LFT/ ALT, AST ECG Others like Echo, US abdomen as indicate #These may best be of out after initial glyce control 	ination creatinine SG ted carried	TREATMENTMETABOLIC TARGETS• Dietary modification• HbA1c • Avoidance of tobacco and restriction/ avoidance of alcohol• HbA1c • Physical activityconditions) where higher targed be acceptable• Pharmacotherapy: • HbA1c < 8.5%: Monotherapy- Metformin • HbA1c 8.5-10%: Dual therapy- Metformin • SU's/TZD/ DPPIVi/SGLT2i /AGI/GLP-1RA • HbA1c > 10%: Basal Insulin+ Metformin + another OAD / triple OAD combination• METABOLIC TARGETS • HbA1c • Dietary modification• HbA1c • HbA1c > 10%: Basal Insulin+ Metformin + another OAD / triple OAD combination• BP=140/90 (130/80 in CKD) LD mg/dl (< 70mg/dl in CAD)				norbid target may sma asma				
MON	IITORING					RE	FERRALS			

MONITORING

Blood glucose; FPG and 2 hours PPG once monthly

· Endocrinology: for uncontrolled hyperglycemia

- more frequent as required including SMBG or CGM
- · HbAlc every 6-12 months (3 monthly if uncontrolled)
- Annual monitoring : ECG, urine ACR (albumin creatinine ratio), dilated fundoscopy, foot examination
- Ophthalmology: at initial evaluation and every year
- Nephrology: for deranged renal function
- Cardiology: for CAD/HF/arrhythmia

SCREENING FOR DIABETES MELLITUS

IN AN APPARENTLY NORMAL ADULT	IN AN ADULT WITH ILLNESS					
 In obese or overweight (BMI ≥ 27.5 	 In any adult/adolescent who presents with one of the following illness/complaints 					
or \geq 23 kg/m ²) with any of the	illness/complaints • Osmotic symptoms (polyuria, polydipsia, polyphagia, nocturia)					
following risk factors	Unexplained weight loss					
• First degree relative with diabetes	 Unexplained depression or dementia Acute coronary syndrome 					
• History of cardiovascular disease	• Deep seated infections (liver abscess, lower lobe pneumonia, tuberculosis,					
• BP (≥ 140/90 mmHg)	pyelonephritis, abscesses, septic arthritis, osteomyelitis)					
• Dyslipidemia (TG > 250 mg/dL,	 Recurrent infections (tinea, oral thrush, onychomycosis, cystitis-urinary tract infection, sinusitis, STI, cellulitis, carbuncle) 					
HDL <40 mg/dl in male, <50 mg/dl	 Non-healing ulcers (foot ulcers-infected/neuropathic) 					
in female	 Exogenous/iatrogenic Cushing's syndrome 					
IIIIeIIIale	IN PREGNANCY					
 Physical inactivity 	• H/O GDM/Pre-existing diabetes					
• Polycystic ovary syndrome (PCOS)	• All pregnant women to be screened in 1 st trimester with FPG					
 Insulin resistance (acanthosis 	• FPG \geq 126 and/or HbA1c \geq 6.5% to be considered pre-existing diabetes					
	• FPG between 92-125 to be considered as GDM					
nigricans)	• All those women with normal screening in 1st trimester to get a 75 g-oral					
 Adults > 30 years of age 	glucose tolerance test done at 24-28 weeks					
 Previous history of GDM 	• All GDM women to be tested 6 weeks post-partum and once every 3 years					
	PREDIABETES: should be tested yearly					
ABBREVIATIONS						

ALT: Alanine transaminase	CGM: Continuous glucose monitor	GDM: Gestational diabetes mellitus	OGTT: Oral glucose tolerance test		
AST: Aspartate aminotransferase	CKD: Chronic kidney disease	HDL: High-density lipoprotein	SMBG: Self-monitoring of blood		
BMI: Body mass index	DTR: Deep tendon reflex	LDL: Low-density lipoprotein	glucose		
BP: Blood pressure	ECG: Electrocardiogram	LFT: Liver function test	TG: Triglyceride		
CAD: Coronary artery disease	FPG: Fasting plasma glucose	OAD: Oral antidiabetic drug			
F KEEP LOW THRESHOLD FOR DIAGNOSIS, MAKE SURE TO FOLLOW UP TO MEET TARGETS					

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (**stw.icmr.org.in**) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.





Standard Treatment Workflow (STW) DIABETIC KETOACIDOSIS ICD-10-E11.10

A CON	May be the initial presentation in TID	M			SESS	
WHEN TO SUSPECT DKA	Pain abdomen Recurrent vomiting		 Sensorium (GCS), pulse rate, blood pressure, respiratory rate, temperature Signs of dehydration (dry tongue, sunken eyes, skin turgor, urine output) 			
IF THERE IS						
HISTORY OF				Mild	Moderate	Severe
	Rapid/labored breathi	na	рН	7.25-7.3	7.0-7.25	<7.0
			HCO ₃	15-18	10-15	<10
<u>ک</u>	Altered sensorium	Altered sensorium		Alert	Mild Drowsiness	Stupor/ Coma
			Sever case: ICU Admission			
Fever/cough/loose stools/burning incturition · VBC			 Spot capillary blood glucose (venous blood preferable in case of shock) Serum ketone/urine ketone by dipstick) VBG (for pH, bicarbonate, anion gap) Na⁺/K⁺/BUN/Creatinine/ECG 			
	MANAG	EMENT				
MONITORI	ng: every 1 hour	•	fluids – 1 l o l by 250-500		line over fir	
 Report if urine output 	is <30ml/hour for 2	initially for children)				
consecutive hours	• Administer regular insulin – 0.1 IU/kg IV then 0.1					
 One hour after startin resolution of DKA 	• Double i	our IV infusion infusion rate after 1 hour		han 10% fall	in blood	
BP and vital signs: even	glucose after 1 hour • When blood glucose < 250 mg/dl, add 5% dextro					
 Blood glucose every 1 	hour	@ 50 ml/hour				
∙ Venous pH, Na, K, HCC	 Supplement potassium before insulin if serum K 33 mEq/L (or ECG changes) 					

- Venous pH, Na, K, HCO_3 : 2-4 hours
- Blood ketones (if available)/Urine for ketones: 12 hourly
- After resolution of DKA: Blood glucose monitoring every 4 hours
- < 3.3 mEq/L (or ECG changes)
- Replace potassium @ 10-20 mEq/hour with insulin infusion if serum K+
- \cdot If pH < 7.0, add sodi 200 ml sterile water
- Bicarbonate should than 6.9 or if pH is le hypotension or if hy



WHEN TO STOP INSULIN INFUSION?

- Patient accepting orally, blood glucose consistently < 250 mg/dl, normalizat of metabolic acidosis
- · Administer SC dose of long/intermediate-acting & short acting insulin at least 30 mins before stopping insulin infusion. Shift to basal-bolus/pre-mixed insulin regimen

COMMON ERRORS/PITFALLS IN DKA DIAGNOSIS AND MANAGEMENT

- Initiating Insulin therapy before I/V fluid therapy
- · Failure to review fluid replacement therapy particularly in elderly patients
- Failure to identify underlying cause
- Search for another cause of obtundation: If the osmolality is <than 320 mOsm/kg H₂O
- · Potassium: may be normal despite depletion of body stores due to metabolic acidosis
- Elevated total leucocyte count does not suggest presence of infection until more than >15 X 109/I
- Monitor for cerebral edema especially in childern

- Body temperature cannot be used as a guide to presence of infection
- Hyperamylasemia: Cannot be used as a marker for diagnosis of pancreatitis
- · Hypertriglycredemia: can cause
- pseudohyponatremia and when marked
- precipitates pancreatitis
- Ketosis may worsen paradoxically with successful treatment initially
- Stopping I/V insulin before S/C insulin given

ABBREVIATIONS

BUN: Blood urea nitrogen **DKA:** Diabetic ketoacidosis **ECG:** Electrocardiogram

GCS: Glasgow coma scale I/V: Intravenous **ICU:** Intensive care unit

SC: Subcutaneous **VBG:** Venous blood gas

KEEP A LOW THRESHOLD FOR TIMELY DIAGNOSIS AND MANAGEMENT OF DKA

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.icmr.org.in) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.





Standard Treatment Workflow (STW) FRAGILITY FRACTURES ICD-10-Z87.310

WHAT ARE FRAGILITY FRACTURES

• To be suspected in fractures resulting from trivial trauma or fall from a standing height or less

• For example fracture neck of femur, forearm fracture (Colle's), vertebral fracture

	Postmenopausal females	Family history of fracture	Previous history of fracture	
Chr.	Renal stone disease	Pancreatitis	Steroid abuse or alternative medications or clinical stigma of cushing's	
WHAT TO ASK?	Premature ovarian failure (less than 40 years)	Diabetes	Chronic diarrhoea or bloating sensation	
	Use of antiepileptics like phenytoin etc Cushings with hypogonadism	Chronic systemic illnesses like rheumatoid arthritis	Smoking, chronic systemic diseases, CKD, CLD, Endocrine disorders, Thyroid disorders, Hypogonadism	

INVESTIGATIONS

Biochemical:	Bone imaging:
Fasting serum calcium, phosphate, alkaline	DXA scan osteoporosis T score-osteoporosis ≥ -2.5 severe
phosphate and albumin (if available) hemogram	osteoporosis= fracture or T score ≥ -3.0
myeloma-proteins in serum or urine	X-ray of fracture site Use Z score for age less than 50 for
Fasting blood glucose PTH (parathyroid)	men and premenopausal women
25 hydroxy Vitamin D, IgA tTg	X-ray lumbar spine (Lateral), pelvis (AP), skull (lateral),
Renal function tests, bone markers beta cross LAP	both hands

Ultrasound abdomen, gall stones, renal stones and nephrocalcinosis, Ultrasound neck, enlarged parathyroid Sestamibi scan for parathyroid enlargement




Fracture neck of the femur



L4 Osteoporotic fracture

HOW TO TREAT?



Sestamibi Scan for parathyroid adenoma

Resuscitate the patient if needed Stabilize the fracture

WHEN AND WHERE TO REFER?

Refer to orthopaedician for fracture management surgical management Refer to endocrinologist for evaluation and treatment of osteoporosis

TREATMENT

- Daily oral calcium 1-1.5 gm/day
- Vitamin D supplementation to maintain serum 250HD levels of 30.0-50 ng/ml
- Stop smoking alcohol

- Inj Zoledronic acid 5mg I/V infusion OR
- Inj Denosumab 60mg S/C every 6 months OR
- Inj rPTH 20 μg S/C daily for maximum 2 years

ABBREVIATIONS

CKD: Chronic kidney disease **CLD:** Chronic liver disease

rPTH: recombinant Parathyroid hormone

• KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (**stw.icmr.org.in**) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.



Ministry of Health and Family Welfare, Government of India



Standard Treatment Workflow (STW) HYPOTHYROIDISM ICD-10-E03.9

WHEN TO SUSPECT HYPOTHYROIDISM ON CLINICAL GROUNDS?

Primary hypothyroidism

Symptoms

Fatigue / Weight gain with poor appetite / Dry skin and cold intolerance / Hair loss / Constipation / Hoarseness of voice / Dyspnea / Muscle weakness and cramps / Menorrhagia (later oligomenorrhea or amenorrhea) / Infertility / Difficulty concentration and poor memory / Paraesthesia / Impaired hearing

Signs

Dry coarse skin / Cool peripheral extremities / Puffy face, hands and feet (myxoedema) / Diffuse alopecia / Goitre / Bradycardia / Peripheral Oedema / Delayed tendon reflex relaxation / Carpel tunnel syndrome / Serous cavity effusions

Congenital hypothyroidism

New born screening (usually asymptomatic)Prolonged icterus / Edema of the eyelids, hands, and feet / Hypotonia / Inactivity / Gestation > 42 wk / Birth weight > 4 kg / Poor feeding / Hypothermia / Abdominal distention / Open posterior fontanelle (> 5 mm)

Central (Secondary) hypothyroidism

Mild-moderate symptoms of hypothyroidism / Signs and symptoms of other pituitary deficits / Manifestations of concomitant hypothalamic pituitary disease Clinical manifestation are less pronounced in secondary hypothyroidism as compared to primary hypothyroidism as there may be multiple pituitary hormone deficiencies which can mask the features of hypothyroidism

Billewicz scoring for diagnosis of Hypothyroidism						
Symptoms	Score if present	Physical signs	Score if present			
Hearing impairment	1	Slow movement	1			
Diminished sweating	1	Periorbital puffiness	1			
Constipation	1	Delayed ankle reflex	1			
Paraesthesia	1	Coarse skin	1			
Haorseness	1	Cold skin	1			
Weight increase	1	Add 1 point for women you	Add 1 point for women younger than 55 years			
Dry skin	1	Total score:12				
Hypothyroid ≥6 points	Intermediate 3-5 points Euthyroid ≤2 points					

Intermediate 3-5 points

HOW DOES ONE CONFIRM CLINICAL SUSPICION OF HYPOTHYROIDISM?

Primary hypothyroidism

Tests to be ordered

TSH FT4 or Total T4 TPO antibodies (if available)

Interpretation Overt hypothyroidism - TSH elevated with low FT4 or T4 levels Subclinical hypothyroidism - TSH elevated centile Confirmatory - TSH > 9 mU/L; FT4

Congenital hypothyroidism

Tests to be ordered after 72 hours TSH FT4 or T4 USG neck, nuclear imaging (Not a must, Do not delay treatment)

Interpretation

Central (Secondary) hypothyroidism

Tests to be ordered FT4 or T4 **TSH** Other pituitary profile Imaging of sella Interpretation

TSH levels normal or low with low FT4 or T4 levels

Screening - TSH > 30 mU/ L; T4 < 10th

with normal FT4 or T4 levels < 0.6 ng/ml							
INITIATING THERAPY							
Primary hypothyroidism		Congenital hypothyroidism	Central (Secondary) hypothyroidism				
Levothyroxine 1.6 to 1.8 mcg per kg per day Single dose, fasting status, no calorie intake for 1 hour thereafter Titrate based on TSH levels Elderly and CAD patients: Start with 12.5–25 mcg/d with 12.5 - 25mcg/d incremental dose every 3–4 wk Consider treating subclinical hypothyroidism in presence of - Large goitre / Positive TPO antibody / ASCVD / Heart failure / Dyslipidemia / Infertility / Depression / refractory anaemia / personal or family history of autoimmune disease		Levothyroxine therapy 10 to 15 mcg per kg per day Single daily dosing Given with breast milk in powdered form Titrate based on FT4 levels and TSH initially, later based on TSH levels	Levothyroxine 1.3 mcg per kg per day Treatment to be initiated only after treating co existing adrenal insufficiency with Hydrocortisone replacement as there is risk of precipitating adrenal crisis, Titrate based on FT4 or T4 levels				
HOW SHOULD THE PATIENT BE FOLLOWED UP?							
Primary hypothyroidism Congenital hypothyroidism			Central (Secondary) hypothyroidism				
 Titrate based on TSH levels Target TSH Young patient's 1–2.5 mU/L Middle-aged patients 1.5–3 Elderly patients < 60 y: > 4.5 mU/L 60–70 y: > 6.0 mU/L 70–80 y: > 7.0 to 8.0 mU/L Once in 3 to 6 months initially, once stable dose is achieved, annual follow up 	<td collection<="" td="" td<=""><td> Titrate based on FT4 or T4 levels Target T4 or FT4 Young people - upper half of normal range Elderly - mid normal range Once in 3 to 6 months initially, once stable dose is achieved, annual follow up </td></td>		<td> Titrate based on FT4 or T4 levels Target T4 or FT4 Young people - upper half of normal range Elderly - mid normal range Once in 3 to 6 months initially, once stable dose is achieved, annual follow up </td>	 Titrate based on FT4 or T4 levels Target T4 or FT4 Young people - upper half of normal range Elderly - mid normal range Once in 3 to 6 months initially, once stable dose is achieved, annual follow up 			
ABBREVIATIONS							
ASCVD: Atherosclerotic cardiovascular c CAD: Coronary Artery Disease		TPO: Thyroid peroxidase TSH: Thyroid-stimulating hormone	USG: Ultrasound sonography				
REFERENCES							
1. Billewicz WZ, Chapman RS, Crooks J, Day ME, Gossage J, Wayne E, et al. Stastical Methods applied to the diagnosis of hypothyroidism. Q J Med.							

1969;38:255-66

KEEP A HIGH THRESHOLD FOR INVASIVE PROCEDURES

This STW has been prepared by national experts of India with feasibility considerations for various levels of healthcare system in the country. These broad guidelines are advisory, and are based on expert opinions and available scientific evidence. There may be variations in the management of an individual patient based on his/her specific condition, as decided by the treating physician. There will be no indemnity for direct or indirect consequences. Kindly visit the website of DHR for more information: (stw.icmr.org.in) for more information. ©Department of Health Research, Ministry of Health & Family Welfare, Government of India.

CONTRIBUTORS

ADVISORY COMMITTEE

CHAIRMAN

Prof. (Dr.) Balram Bhargava, Secretary-DHR and DG-ICMR

VICE CHAIRMAN

Dr. Nikhil Tandon, AlIMS, New Delhi

MEMBERS

Dr. Anil Bhansali, Endocrinology, PGIMER, Chandigarh Mrs. Anu Nagar, Jt. Secretary, Dept. of Health Research, MoHFW, Govt. of India Dr. Ashok Deorari, Neonatology, AIIMS, New Delhi Dr. Binod K Khaitan, Dermatology, AIIMS, New Delhi Dr. Pramod Garg, Gastroenterology, TISHTI, Faridabad Dr. Radhika Tandon, Ophthalmology, AIIMS, New Delhi Dr. Rajdeep Singh, General Surgery, MAMC, New Delhi Dr. S. C. Goel, Orthopaedics, BHU, Varanasi Dr. Sandeep Agarwala, Paediatrics, AIIMS, New Delhi Dr. Sudeep Gupta, Oncology, TMC, Mumbai Dr. T. Sundararaman, Former Executive Director, NHSRC, New Delhi Ex officio Additional Secretary & MD (NHM), MoHFW, Govt. of India Ex officio Director General Health Services / Representative

EDITORIAL BOARD

EXTERNAL COMMITTEE

Dr. Anil Bhansali, Endocrinology, PGIMER, Chandigarh Dr. Anurag Srivastava, Oncology, AIIMS, New Delhi Dr. Deepika Pandhi, Dermatology, UCMS, New Delhi Dr. Neeraj Gupta, Paediatrics, AIIMS, Jodhpur Dr. Radhika Tandon, Ophthalmology, RP Centre, AIIMS, New Delhi Dr. Rajdeep Singh, General Surgery, MAMC, New Delhi Dr. Usha Dutta, Gastroenterology, PGIMER, Chandigarh

Dr. Vijay Jain, Orthopaedics, RML, New Delhi

INTERNAL COMMITTEE

Dr. R S Dhaliwal, Scientist G & Head (NCD), ICMR Dr. Ashoo Grover, Scientist F, ICMR Dr. Lokesh Kumar Sharma, Scientist E, ICMR Dr. Aparna Mukherjee, Scientist E, ICMR Dr. Jerin Jose Cherian, Scientist D, ICMR Dr. Saumya Srivastava Aggarwal, Project Scientist C, ICMR



EXPERT GROUPS

ENDOCRINOLOGY

CHAIR

Dr. Anil Bhansali, PGIMER, Chandigarh

CO-CHAIR

Dr. Eesh Bhatia, SGPGI, Lucknow

MEMBERS

Dr. B Ganpathi, St. JMCH, Bengaluru

- Maj. Gen. Dr. Narendra Kotwal, AHRR, New Delhi
- Dr. Rajesh Rajput, PGIMS, Rohtak
- Dr. Ravinder Goswami, AllMS, New Delhi
- Dr. Subhankar Choudhary, IPGMER, Kolkata
- Dr. V Mohan, Dr. Mohan's DSC, Chennai



Dr Mansukh Mandaviya Union Minister for Health & Family Welfare

PATRON

CHIEF PATRON

Dr Bharati Pravin Pawar Union Minister of State for Health & Family Welfare

ADVISOR

Prof. Dr Balram Bhargava Secretary, DHR & Director General, ICMR

ICMR STW TEAM

Dr R S Dhaliwal, Scientist G & Head(NCD), ICMR Dr Ashoo Grover, Scientist F, ICMR Dr Lokesh Kumar Sharma, Scientist E, ICMR Dr Jerin Jose Cherian, Scientist D, ICMR Mr Neeraj Parmar, Technical Officer A, ICMR Dr Saumya Srivastava Aggarwal, Project Scientist C, ICMR Mr Dhiraj Kumar, Project Graphics Designer, ICMR

ADMINISTRATION

Shri R. Ramakrishnan, Sr DDG (Admin.), ICMR Shri Rajeev Roy, Sr FA, ICMR Dr R Lakshminarayanan, DDG(Admin.), ICMR Shri Jagdish Rajesh, ADG (Admin.), ICMR Shri Vinod Sharma, ADG(Finance), ICMR



icma



STANDARD TREATMENT WORKFLOWS of India

Scan to access Standard Treatment Workflows



Web Portal



Google Play



App Store




Department of Health Research Ministry of Health and Family Welfare, Government of India





STANDARD TREATMENT WORKFLOWS of India



PARTNERS





2022 EDITION